Patent Assignment
Reel/Frame 075670/0001
Confirmatory Grant of Security Interest in United States Patents
Recorded: 2026-05-26
Pages: 15
Assignor
NEUROCRINE BIOSCIENCES, INC.
Executed: 2026-05-14
Assignee
JPMORGAN CHASE BANK, N.A.
131 S DEARBORN ST, FLOOR 04, ATTENTION: LOAN AND AGENCY SERVICING, CHICAGO, ILLINOIS, 60603-5506
Covered Properties
(92)
Crf Receptor Antagonists and Methods of Use
Application:
18/042,748 →
Publication:
US US20240024330A1
CRF1 Receptor Antagonist, Pharmaceutical Formulations and Solid Forms Thereof for the Treatment of Congenital Adrenal Hyperplasia
Application:
17/311,310 →
Publication:
US US20220023266A1
Compounds and Compositions as GPR52 Modulators
Application:
19/124,526 →
Publication:
US US20260167615A1
Dosage Regime of Crinecerfont for Treating Congenital Adrenal Hyperplasia
Application:
19/469,981 →
Dosage Regime of Crinecerfont for Treating Congenital Adrenal Hyperplasia in a Pediatric Subject
Application:
19/482,565 →
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
Application:
19/012,563 →
Publication:
US US20250282792A1
GPR52 Modulators and Methods of Use
Application:
18/288,060 →
Publication:
US US20240208907A1
Improvement, Maintenance or Reduction of Decline of Motor Function Associated with Huntington Disease Using Valbenazine
Application:
19/583,542 →
Methods for Administration of Certain Muscarinic Receptor Agonists
Application:
63/850,894 →
Methods for Administration of Certain Muscarinic Receptor Agonists
Application:
63/850,914 →
Methods for the Administration of Certain VMAT2 Inhibitors
Application:
19/186,745 →
Publication:
US US20260048042A1
Methods for the Administration of Certain VMAT2 Inhibitors
Application:
18/286,944 →
Publication:
US US20240197714A1
Methods for the Combined Administration of Deutetrabenazine and a CYP2D6 Inhibitor
Application:
18/286,935 →
Publication:
US US20240207247A1
Methods of Screening for VMAT2 Inhibitors
Application:
18/684,426 →
Publication:
US US20250064990A1
Methods of Synthesis
Application:
19/508,160 →
Methods of Treatment
Application:
63/851,014 →
Methods of Treatment
Application:
63/850,856 →
Muscarinic Receptor 4 Antagonists and Methods of Use
Application:
18/293,329 →
Publication:
US US20250092022A1
Muscarinic Receptor 4 Antagonists and Methods of Use
Application:
17/797,368 →
Publication:
US US20230129359A1
NLRP3 Inflammasome Inhibitor and Use Thereof
Application:
19/510,198 →
Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
Application:
16/105,396 →
Publication:
US US20190054088A1
Processes for the Synthesis of Valbenazine
Application:
18/288,311 →
Publication:
US US20240239791A1
Processes for the Synthesis of Valbenazine
Application:
17/641,705 →
Publication:
US US20220363680A1
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CRF RECEPTOR ANTAGONISTS
SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS
SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS
Application:
19/182,823 →
Publication:
US US20250333413A1
Treatment of Congenital Adrenal Hyperplasia
Application:
18/222,011 →
Publication:
US US20240058342A1
Valbenazine Compositions
Application:
18/705,079 →
Publication:
US US20250000805A1
Valbenazine for Use in the Add-on Treatment of Schizophrenia
Application:
18/575,022 →
Publication:
US US20240342159A1
Valbenazine for Use in the Treatment of Dyskinesia Due to Cerebral Palsy
Application:
18/575,126 →
Publication:
US US20240342160A1
Valbenazine, a VMAT2 Inhibitor, as a Free Base a Tosylate or Ditosylate Salt, for Use in the Treatment of Chorea Associated with Huntington's Disease
Application:
18/844,531 →
[9,10-Dimethoxy-3-(2-Methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-Pyrido-[2,1-A]Isoquinolin-2-Yl]Methanol and Compounds, Compositions and Methods Relating Thereto
[9,10-Dimethoxy-3-(2-Methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-Pyrido-[2,1-A]Isoquinolin-2-Yl]Methanol and Compounds, Compositions and Methods Relating Thereto
[9,10-Dimethoxy-3-(2-Methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-Pyrido-[2,1-A]Isoquinolin-2-Yl]Methanol and Compounds, Compositions and Methods Relating Thereto
Compounds of Formulas (Vii), (Viii), (Ix), (Xi), (Xii), (Xiii), and (Xiv) as Muscarinic Receptor 4 (M4) Antagonists for Treating Neurological Diseases
Crf Receptor Antagonists and Methods of Use
Crf Receptor Antagonists and Methods Relating Thereto
Compounds, Pharmaceutical Composition and Methods Relating Thereto
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
Gonadotropin-Releasing Hormone Receptor Antagonists and Methods Relating Thereto
GPR52 Modulators and Methods of Use
High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
Hydrocortisone Controlled Release Formulation
Hydrocortisone Controlled Release Formulation
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Methods for the Administration of Certain VMAT2 Inhibitors
Muscarinic Receptor 4 Antagonists and Methods of Use
New Compounds, Pharmaceutical Composition and Methods Relating Thereto
Pharmaceutical Compositions Comprising an Antipsychotic Drug and a VMAT2 Inhibitor and Uses Thereof
Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
Pyrazolo [1,5-Alpha] Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists
Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists
Substituted 3-Isobutyl-9,10-Dimethoxy-1,3,4,6,7,11B-Hexahydro-2H-Pyrido[2,1-a]Isoquinolin-2-Ol Compounds and Methods Relating Thereto
Substituted 3-Isobutyl-9,10-Dimethoxy-1,3,4,6,7,11B-Hexahydro-2H-Pyrido[2,1-a]Isoquinolin-2-Ol Compounds and Methods Relating Thereto
SUBSTITUTED PYRIDO[2,1-a]ISOQUINOLINES AS VMAT2 INHIBITORS
Substituted Triazoles and Methods Relating Thereto
Substituted Triazoles and Methods Relating Thereto
Substituted Triazoles and Methods Relating Thereto
Substituted Triazoles and Methods Relating Thereto
Synthetic Methods for Preparation of 4-(2-Chloro-4-Methoxy-5-Methylphenyl)-N-[(1S)-2-Cyclopropyl-1-(3-Fluoro-4-Methylphenyl)Ethyl]-5-Methyl-N-Prop-2-Ynyl-1,3-Thiazol-2-Amine
Synthetic Methods for Preparation of 4-(2-Chloro-4-Methoxy-5-Methylphenyl)-N-[(1S)-2-Cyclopropyl-1-(3-Fluoro-4-Methylphenyl)Ethyl]-5-Methyl-N-Prop-2-Ynyl-1,3-Thiazol-2-Amine
Patent:
12,582,634 →
Application:
17/782,617 →
SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
Synthetic Methods for Preparation of (S)-(2R,3R,11BR)-3-Isobutyl-9,10-Dimethoxy-2,3,4,6,7,11B-Hexahydro-1H-Pyrido[2,1,-a]Isoquinolin-2-Yl 2-Amino-3-Methylbutanoate Di(4-Methylbenzenesulfonate)
SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
Tamper-Resistant Pharmaceutical Dosage Forms
Tamper-Resistant Pharmaceutical Dosage Forms and Process for Making Same
Treatment of Congenital Adrenal Hyperplasia
Treatment of Congenital Adrenal Hyperplasia
Treatment of Congenital Adrenal Hyperplasia
Valbenazine Salts and Polymorphs Thereof
Valbenazine Salts and Polymorphs Thereof
Valbenazine Salts and Polymorphs Thereof
Valbenazine Salts and Polymorphs Thereof
VMAT2 Inhibitor Compounds and Compositions Thereof
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 20, 2021
From: PARKS, STACY; VICKERY, ANTHONY D.; DOWNING, KRISTIE M.
To: BEND RESEARCH, INC.
Reel/Frame 056910/0769 →
Assignment of Assignor's Interest
Jul 20, 2021
From: SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
To: SANOFI
Reel/Frame 056911/0169 →
Assignment of Assignor's Interest
Jul 20, 2021
From: BEND RESEARCH, INC.
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 056911/0090 →
Assignment of Assignor's Interest
Jul 20, 2021
From: QUOTIENT SCIENCES LIMITED
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 056911/0023 →
Assignment of Assignor's Interest
Jul 20, 2021
From: IYOHA, KINGSLEY; NGWENYA-JONES, AYANDA; MEHTON, GURVINDER SINGH
To: QUOTIENT SCIENCES LIMITED
Reel/Frame 056910/0984 →
Assignment of Assignor's Interest
Jul 20, 2021
From: CHARLIER, ANNE
To: SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
Reel/Frame 056910/0857 →
Assignment of Assignor's Interest
Jul 20, 2021
From: FARBER, ROBERT H.; LOEWEN, GORDON RAPHAEL; ZHANG, XIAOPING; GIRI, NAGDEEP
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 056910/0684 →
Assignment of Assignor's Interest
Aug 26, 2022
From: ASHWEEK, NEIL J.; WILLIAMS, JOHN P.; ZEGELMAN, LEV ALEXANDER; COSTA, CHRISTINA MARIE
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 060911/0053 →
Assignment of Assignor's Interest
Feb 15, 2023
From: HARRIOTT, NICOLE; PAGANO, NICHOLAS; LEY, CORINNE ROSE
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 062751/0598 →
Assignment of Assignor's Interest
Jun 13, 2023
From: HARRIOTT, NICOLE; PAGANO, NICHOLAS; BOON, BYRON A.
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 063930/0106 →
Assignment of Assignor's Interest
Jul 17, 2023
From: GRIGORIADIS, DIMITRI E.
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 064281/0339 →
Assignment of Assignor's Interest
Oct 27, 2023
From: LOEWEN, GORDON; BRAR, SATJIT
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 065366/0400 →
Assignment of Assignor's Interest
Oct 27, 2023
From: LOEWEN, GORDON RAPHAEL; SMITH, EVAN; FARBER, ROBERT H.; CHAN, JEAN L.
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 065366/0339 →
Assignment of Assignor's Interest
Oct 27, 2023
From: LOEWEN, GORDON; BRAR, SATJIT
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 065366/0359 →
Assignment of Assignor's Interest
Nov 10, 2023
From: CUEVA-GARCIA, JUAN PABLO; ASHWEEK, NEIL J.; REGAN, COLLIN
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 065527/0801 →
Assignment of Assignor's Interest
Dec 28, 2023
From: ANGELOV, ANGEL S.
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 065973/0376 →
Assignment of Assignor's Interest
Jan 30, 2024
From: HARRIOTT, NICOLE; PAGANO, NICHOLAS; LEY, CORINNE ROSE
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 066286/0419 →
Assignment of Assignor's Interest
Jan 30, 2024
From: TUCKER, JOHN LLOYD
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 066297/0451 →
Assignment of Assignor's Interest
Feb 22, 2024
From: TERRY-LORENZO, RYAN; HAUBENBERGER, DIETRICH; GIRI, NAGDEEP
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 066525/0375 →
Assignment of Assignor's Interest
Apr 26, 2024
From: MOORE, RICHARD ALEXANDER, JR.; SHORT, AMELIA M., JR.; HUANG, ZHONGHUI M., JR.
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 067236/0469 →
Corrective Assignment to Correct the Conveying Party Data Previously Recorded at Reel: 067236 Frame: 0469. Assignor(S) Hereby Confirms the Assignment.
Apr 29, 2024
From: MOORE, RICHARD ALEXANDER, JR.; SHORT, AMELIA M.; HUANG, ZHONGHUI
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 067252/0596 →
Assignment of Assignor's Interest
Dec 6, 2024
From: JAYANTH, JAYANTHY; SPENCE, KEVIN C.; CHWALISZ, KRISTOF; OWENS, CHARLOTTE D.
To: ABBVIE INC.
Reel/Frame 069531/0201 →
Assignment of Assignor's Interest
Dec 6, 2024
From: PELOSO, PAUL M.
To: ABBVIE INC.
Reel/Frame 069506/0043 →
Assignment of Assignor's Interest
Dec 6, 2024
From: MCCLELLAND, GREGORY A.; STEPANENKO, ANNA V.
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 069506/0046 →
Assignment of Assignor's Interest
Jan 8, 2025
From: BEATON, GRAHAM; CHEN, MI; COON, TIMOTHY RICHARD; EWING, TODD
To: NEUROCRINE BIOSCIENCES, INC.
Reel/Frame 069841/0472 →